Daily Roundup

CSL Invests $355 Million in Rare Disease Treatment Partnership

CSL Ltd. is making a significant bet on rare kidney and liver diseases through an exclusive agreement with Alentis Therapeutics. The deal centers on lixudebart, a potential first-in-class treatment currently being tested for conditions like ANCA-associated vasculitis and rapidly progressive glomerulonephritis. CSL will kick off with an initial payment of US$355 million, with the potential for up to an additional US$1.2 billion in commercial milestone payments down the line. The company will also fund the completion of ongoing Phase 2 trials and planned Phase 3 studies, plus additional development work. If lixudebart makes it through the pipeline, CSL and Alentis will share future profits from the treatment.

Wound Care Innovation Shows Real Promise for Diabetic Patients

Over at Aroa Biosurgery, there's encouraging news for people struggling with diabetic foot ulcers. The company's Symphony product has delivered impressive results in a randomized controlled trial involving 143 patients across 10 US sites. When Symphony was added to standard care, 55% of diabetic foot ulcers achieved complete wound closure within 12 weeks, compared to just 35% with standard care alone. Even better, the average healing time dropped by nearly a week—from 73.2 days to 65.4 days. These results, published in the International Wound Journal, suggest Symphony could become a meaningful option for patients dealing with this challenging condition.

Gold Miners Report Strong Quarter Despite Mixed Operational Challenges

The gold sector had a solid quarter, with several producers hitting their targets. Predictive Discovery Ltd. poured 52,866 ounces of gold during the three months ended September 30, with its Kiniero operation running above nameplate capacity and achieving impressive gold recoveries of 88.3%. However, production at the company's Nampala mine was hampered by ore access issues as pit cutback activities continued. Despite this, Predictive Discovery ended the quarter in a strong financial position with US$405 million in cash and bullion.

Capricorn Metals also delivered solid numbers, producing 31,218 ounces of gold in Q1 and staying on track with its full-year guidance. The real highlight here is that the company successfully completed its Karlawinda Expansion Project on schedule and within budget, boosting processing capacity to 6.5 million tonnes per annum. That expansion should support production of around 150,000 ounces annually going forward. Capricorn is guiding for 137,000 to 147,000 ounces in FY27 at an all-in sustaining cost of $1,900 to $2,100 per ounce.

Exploration Upside Emerging at Kiniéro Gold Project

Predictive Discovery also announced encouraging exploration results from its Kiniéro Gold Project in Guinea, with drilling returning significant high-grade intercepts, including 28.35 meters grading 5.87 grams per tonne of gold. The company's structural interpretation suggests these veins form part of a larger, interconnected system with real continuity potential. With a 2027 drilling campaign planned to comprise roughly 1,800 holes and 140,000 meters, Predictive Discovery is positioning itself to unlock further mineral resource upside and extend mine life.

Long-Term Patient Commitment Signals Confidence in FSGS Treatment

Dimerix Limited hit a notable milestone when the first patient completed four years in its DMX-200 clinical program for focal segmental glomerulosclerosis. The patient finished both the two-year ACTION3 Phase 3 trial and the subsequent two-year Open Label Extension study. What's particularly telling is that over 90% of eligible patients who completed the Phase 3 trial chose to continue into the extension study, suggesting strong confidence in the treatment's safety and efficacy profile. The company is also planning to offer continued access through a post-trial access program, pending ethics approval.